Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2023-11-14 AGM Information
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Chairman's Address to 2023 Annual General Meeting 2 pages 114.0KB
AGM Information Classification · 95% confidence The document is titled 'Chairman Address to 2023 Annual General Meeting' and is dated 15 November 2023. It contains a detailed speech by the Chairman addressing shareholders at the AGM, including a review of the company's financial year, clinical trial progress, corporate governance activities, and outlook. The content is typical of presentations or materials shared during an Annual General Meeting. There is no indication that this is a full Annual Report (10-K) or an earnings release, nor does it contain standalone audit information or detailed financial statements. The document is not a voting result announcement or a proxy solicitation. It is clearly a presentation or address given at the AGM, fitting the definition of AGM Information (AGM-R). The document length (7439 characters) supports it being a substantive address rather than a brief announcement or certification. Therefore, the classification is AGM-R with high confidence.
2023-11-14 English
2023 Annual General Meeting Presentation 17 pages 2.0MB
AGM Information Classification · 100% confidence The document is titled 'AGM Presentation' and includes detailed presentation slides with corporate strategy, clinical pipeline, capital summary, and forward-looking statements. It is explicitly described as a presentation prepared for the Annual General Meeting (AGM) of Neurotech International Limited. The content is typical of an investor presentation given at an AGM, including business updates, strategy, and clinical development progress. There is no indication that this is a full annual report, earnings release, or other regulatory filing. The length (15,000 characters) and the nature of the content (slides, forward-looking statements, disclaimers) align with an AGM presentation rather than a report or announcement of a report. Therefore, the correct classification is AGM Information (AGM-R).
2023-11-14 English
Results of Meeting 2 pages 113.7KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement dated 15 November 2023 reporting the results of an Annual General Meeting (AGM) for Neurotech International Limited. It details the outcome of shareholder votes on various resolutions, including adoption of the remuneration report, re-election of a director, approval of mandates, and ratification of prior share issues. The content focuses on the voting results from the AGM rather than the meeting materials or presentations themselves. The document length is 4133 characters, which is relatively short and consistent with a voting results announcement rather than a full AGM report or presentation. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-11-14 English
New Constitution 75 pages 1.1MB
Governance Information Classification · 95% confidence The document is an announcement from Neurotech International Limited regarding the approval of a new Constitution at the Annual General Meeting held on 15 November 2023. It includes a statement that a copy of the new Constitution is attached. The content focuses on corporate governance matters, specifically the company's constitution, which is a governance document outlining internal rules and shareholder rights. There is no financial data, earnings information, or detailed management discussion. The document is not a full report but an announcement of a governance change approved at the AGM. Therefore, the most appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content of the constitution support this classification rather than a brief announcement or a regulatory filing. Confidence is high due to clear governance focus and the nature of the document.
2023-11-14 English
Neurotech Receives $3.17 Million R&D Tax Incentive Refund 1
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 14 November 2023, reporting that Neurotech International Limited has received a $3.17 million R&D tax incentive refund for the financial year ended 30 June 2023. The content focuses on the receipt of a government tax refund and its impact on the company's cash balance and operations funding. There are no financial statements, detailed financial results, or comprehensive report data included. The document is relatively short (2989 characters) and serves as an update on a specific financial event rather than a full financial report or earnings release. It is not a report publication announcement since it does not mention the release or availability of a report, nor is it a certification or legal proceeding. The nature of the announcement fits best under Capital/Financing Update (CAP) as it relates to a financial inflow impacting the company's capital and funding status.
2023-11-13 English
Q&A on Phase I/II PANDAS/PANS Clinical Trial Results 4 pages 176.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 1 November 2023 from Neurotech International Limited. It discusses clinical trial results for a Phase I/II trial of NTI164 for PANDAS/PANS, including detailed Q&A about the trial outcomes, safety, and future plans such as orphan drug designation and further trials. The content is focused on clinical trial results and company strategy related to drug development and commercialization. It is not a full financial report, earnings release, or regulatory filing. It is also not a presentation or transcript but a detailed announcement with substantive information about clinical trial results and company plans. Given the nature of the document as an announcement of clinical trial results and company updates, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document is too detailed and lengthy to be a simple report publication announcement (RPA) and does not contain financial statements or earnings data to be classified as an earnings release or interim report.
2023-10-31 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.